Antiplatelet therapy: Views from the experts

J. Donald Easton, Hans Christoph Diener, Natan M. Bornstein, Karl Einhäupl, Michael Gent, Markku Kaste, Ralph L Sacco, Jan G P Tijssen, Jan Van Gijn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Antiplatelet therapy is recommended for stroke prevention in persons with a history of thromboembolic stroke or transient ischemic attack (TIA) that is not of cardiac origin. Aspirin was the first antiplatelet agent to be used in this context and is still the most frequently prescribed preventive treatment for ischemic stroke. However, because the results of clinical studies with aspirin have been inconsistent, the dose of aspirin required for stroke prevention in persons with cerebrovascular disease has been a subject of debate among stroke neurologists. In the present discussion, low-dose aspirin is generally regarded by the experts as equivalent in effectiveness to high-dose aspirin, and its higher tolerability has the potential to significantly increase compliance with long-term therapy. Higher aspirin doses may have clinical utility in particular settings, but this requires further study. Despite the controversy, aspirin is now recognized as the treatment standard which other antiplatelet agents are compared. Antiplatelet agents that may be more effective than aspirin have now been developed. Although each of these agents has been directly compared with aspirin in a large, randomized clinical trial, the lack of direct comparisons among these alternative antiplatelet therapies complicates decisions regarding long-term care of patients with cerebrovascular disease. An international panel of stroke neurologists reports that their selection of antiplatelet therapies for patients with prior history of TIA or stroke depends most heavily on drug efficacy and safety issues and is limited by availability (approval status of alternatives).

Original languageEnglish
JournalNeurology
Volume53
Issue number7 SUPPL. 4
StatePublished - Oct 29 1999
Externally publishedYes

Fingerprint

Aspirin
Stroke
Platelet Aggregation Inhibitors
Cerebrovascular Disorders
Therapeutics
Transient Ischemic Attack
Long-Term Care
Complementary Therapies
Randomized Controlled Trials
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Easton, J. D., Diener, H. C., Bornstein, N. M., Einhäupl, K., Gent, M., Kaste, M., ... Van Gijn, J. (1999). Antiplatelet therapy: Views from the experts. Neurology, 53(7 SUPPL. 4).

Antiplatelet therapy : Views from the experts. / Easton, J. Donald; Diener, Hans Christoph; Bornstein, Natan M.; Einhäupl, Karl; Gent, Michael; Kaste, Markku; Sacco, Ralph L; Tijssen, Jan G P; Van Gijn, Jan.

In: Neurology, Vol. 53, No. 7 SUPPL. 4, 29.10.1999.

Research output: Contribution to journalArticle

Easton, JD, Diener, HC, Bornstein, NM, Einhäupl, K, Gent, M, Kaste, M, Sacco, RL, Tijssen, JGP & Van Gijn, J 1999, 'Antiplatelet therapy: Views from the experts', Neurology, vol. 53, no. 7 SUPPL. 4.
Easton JD, Diener HC, Bornstein NM, Einhäupl K, Gent M, Kaste M et al. Antiplatelet therapy: Views from the experts. Neurology. 1999 Oct 29;53(7 SUPPL. 4).
Easton, J. Donald ; Diener, Hans Christoph ; Bornstein, Natan M. ; Einhäupl, Karl ; Gent, Michael ; Kaste, Markku ; Sacco, Ralph L ; Tijssen, Jan G P ; Van Gijn, Jan. / Antiplatelet therapy : Views from the experts. In: Neurology. 1999 ; Vol. 53, No. 7 SUPPL. 4.
@article{82d93440a85a462a93c96839a45c80fd,
title = "Antiplatelet therapy: Views from the experts",
abstract = "Antiplatelet therapy is recommended for stroke prevention in persons with a history of thromboembolic stroke or transient ischemic attack (TIA) that is not of cardiac origin. Aspirin was the first antiplatelet agent to be used in this context and is still the most frequently prescribed preventive treatment for ischemic stroke. However, because the results of clinical studies with aspirin have been inconsistent, the dose of aspirin required for stroke prevention in persons with cerebrovascular disease has been a subject of debate among stroke neurologists. In the present discussion, low-dose aspirin is generally regarded by the experts as equivalent in effectiveness to high-dose aspirin, and its higher tolerability has the potential to significantly increase compliance with long-term therapy. Higher aspirin doses may have clinical utility in particular settings, but this requires further study. Despite the controversy, aspirin is now recognized as the treatment standard which other antiplatelet agents are compared. Antiplatelet agents that may be more effective than aspirin have now been developed. Although each of these agents has been directly compared with aspirin in a large, randomized clinical trial, the lack of direct comparisons among these alternative antiplatelet therapies complicates decisions regarding long-term care of patients with cerebrovascular disease. An international panel of stroke neurologists reports that their selection of antiplatelet therapies for patients with prior history of TIA or stroke depends most heavily on drug efficacy and safety issues and is limited by availability (approval status of alternatives).",
author = "Easton, {J. Donald} and Diener, {Hans Christoph} and Bornstein, {Natan M.} and Karl Einh{\"a}upl and Michael Gent and Markku Kaste and Sacco, {Ralph L} and Tijssen, {Jan G P} and {Van Gijn}, Jan",
year = "1999",
month = "10",
day = "29",
language = "English",
volume = "53",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7 SUPPL. 4",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Views from the experts

AU - Easton, J. Donald

AU - Diener, Hans Christoph

AU - Bornstein, Natan M.

AU - Einhäupl, Karl

AU - Gent, Michael

AU - Kaste, Markku

AU - Sacco, Ralph L

AU - Tijssen, Jan G P

AU - Van Gijn, Jan

PY - 1999/10/29

Y1 - 1999/10/29

N2 - Antiplatelet therapy is recommended for stroke prevention in persons with a history of thromboembolic stroke or transient ischemic attack (TIA) that is not of cardiac origin. Aspirin was the first antiplatelet agent to be used in this context and is still the most frequently prescribed preventive treatment for ischemic stroke. However, because the results of clinical studies with aspirin have been inconsistent, the dose of aspirin required for stroke prevention in persons with cerebrovascular disease has been a subject of debate among stroke neurologists. In the present discussion, low-dose aspirin is generally regarded by the experts as equivalent in effectiveness to high-dose aspirin, and its higher tolerability has the potential to significantly increase compliance with long-term therapy. Higher aspirin doses may have clinical utility in particular settings, but this requires further study. Despite the controversy, aspirin is now recognized as the treatment standard which other antiplatelet agents are compared. Antiplatelet agents that may be more effective than aspirin have now been developed. Although each of these agents has been directly compared with aspirin in a large, randomized clinical trial, the lack of direct comparisons among these alternative antiplatelet therapies complicates decisions regarding long-term care of patients with cerebrovascular disease. An international panel of stroke neurologists reports that their selection of antiplatelet therapies for patients with prior history of TIA or stroke depends most heavily on drug efficacy and safety issues and is limited by availability (approval status of alternatives).

AB - Antiplatelet therapy is recommended for stroke prevention in persons with a history of thromboembolic stroke or transient ischemic attack (TIA) that is not of cardiac origin. Aspirin was the first antiplatelet agent to be used in this context and is still the most frequently prescribed preventive treatment for ischemic stroke. However, because the results of clinical studies with aspirin have been inconsistent, the dose of aspirin required for stroke prevention in persons with cerebrovascular disease has been a subject of debate among stroke neurologists. In the present discussion, low-dose aspirin is generally regarded by the experts as equivalent in effectiveness to high-dose aspirin, and its higher tolerability has the potential to significantly increase compliance with long-term therapy. Higher aspirin doses may have clinical utility in particular settings, but this requires further study. Despite the controversy, aspirin is now recognized as the treatment standard which other antiplatelet agents are compared. Antiplatelet agents that may be more effective than aspirin have now been developed. Although each of these agents has been directly compared with aspirin in a large, randomized clinical trial, the lack of direct comparisons among these alternative antiplatelet therapies complicates decisions regarding long-term care of patients with cerebrovascular disease. An international panel of stroke neurologists reports that their selection of antiplatelet therapies for patients with prior history of TIA or stroke depends most heavily on drug efficacy and safety issues and is limited by availability (approval status of alternatives).

UR - http://www.scopus.com/inward/record.url?scp=0032717861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032717861&partnerID=8YFLogxK

M3 - Article

C2 - 10532646

AN - SCOPUS:0032717861

VL - 53

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7 SUPPL. 4

ER -